AstraZeneca's bid for Omthera Pharmaceuticals cleared by US antitrust officials
NYSE-listed AstraZeneca received approval from US antitrust authorities to buy Nasdaq-listed specialty pharmaceutical company Omthera Pharmaceuticals, according to a list released by the US Federal Trade Commission Thursday.NYSE-listed AstraZeneca received approval...To view the full article, register now.
Already a subscriber? Click here to view full article